Skip to main content

Table 2 Schedule of evaluation of the study

From: Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

 

Entry

Treatment

1 day

3 days

7 days

30 days

180 days

1 year

2 years

Inclusion/exclusion criteria

X

        

Signed consent form

X

        

Medical/treatment history

X

        

Vital signs

X

X

X

X

X

    

Laboratory tests

X

X

X

X

X

    

Respiratory function test

X

        

ECG

X

   

X

    

Body CT

X

     

X

X

X

Brain CT/MRI

X

       

X

Bone scintigraphy/ whole body PET

X

       

X

Surgical procedure

 

X

      

X

Medication

 

X

X

X

X

 

X

X

X

Cancer recurrence

 

X

X

X

X

X

X

X

X

Adverse events

 

X

X

X

X

    
  1. ECG electrocardiogram, CT computed tomography, MRI magnetic resonance imaging, PET positron emission tomography
Back to article page

Trials

ISSN: 1745-6215